Protocol for AREST: Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation—A Randomized Controlled Trial of Early Anticoagulation After Acute Ischemic Stroke in Atrial Fibrillation
| العنوان: | Protocol for AREST: Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation—A Randomized Controlled Trial of Early Anticoagulation After Acute Ischemic Stroke in Atrial Fibrillation |
|---|---|
| المؤلفون: | Nhi Tran, Michael G. Fradley, Kevin E. Kip, Swetha Renati, Bonnie Kirby, Ryan C. Martin, Andrea C. Bozeman, W. Scott Burgin, Thomas Kasprowicz, David Z. Rose, Ryan Murtagh, Arthur J. Labovitz, John N. Meriwether, Maxim Mokin, Nicholas Hilker, Natasha Wick, Tara McTigue, Aarti Patel |
| المصدر: | Frontiers in Neurology Frontiers in Neurology, Vol 10 (2019) |
| بيانات النشر: | Frontiers Media SA, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | acute ischemic stroke, medicine.medical_specialty, apixaban, direct oral anticoagulant, 030204 cardiovascular system & hematology, lcsh:RC346-429, anticoagulation timing, law.invention, Study Protocol, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, law, Internal medicine, medicine, atrial fibrillation, cardiovascular diseases, Stroke, lcsh:Neurology. Diseases of the nervous system, business.industry, Absolute risk reduction, Warfarin, Atrial fibrillation, Guideline, medicine.disease, Clinical trial, Neurology, transient ischemic attack, Cardiology, Apixaban, Neurology (clinical), business, 030217 neurology & neurosurgery, medicine.drug |
| الوصف: | Background: Optimal timing to initiate anticoagulation after acute ischemic stroke (AIS) from atrial fibrillation (AF) is currently unknown. Compared to other stroke etiologies, AF typically provokes larger infarct volumes and greater concern of hemorrhagic transformation, so seminal randomized trials waited weeks to months to begin anticoagulation after initial stroke. Subsequent data are limited and non-randomized. Guidelines suggest anticoagulation initiation windows between 3 and 14 days post-stroke, with Class IIa recommendations, and level of evidence B in the USA and C in Europe. Aims: This open-label, parallel-group, multi-center, randomized controlled trial AREST (Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation) is designed to evaluate the safety and efficacy of early anticoagulation, based on stroke size, secondary prevention of ischemic stroke, and risks of subsequent hemorrhagic transformation. Methods: Subjects are randomly assigned in a 1:1 ratio to receive early apixaban at day 0–3 for transient ischemic attack (TIA), 3–5 for small-sized AIS ( |
| تدمد: | 1664-2295 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1a89cbe352643aea1baf9a490f4664d https://doi.org/10.3389/fneur.2019.00975 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....f1a89cbe352643aea1baf9a490f4664d |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 16642295 |
|---|